E156 Micro-Paper · Africa Clinical Trials

Spatial Equity Indices

A composite measure of how fairly clinical research is distributed geographically.

Africa SEI
0.18
Europe SEI
0.74
Global Average
0.52
Equity Gap
4.1x
Africa scored 0.18 on the composite index compared to 0.74 for Europe and 0.81 for the United States, indicating a four-fold spatial equity deficit.
Spatial Equity Index (0=inequitable, 1=equitable)Europe74Americas61Asia-Pacific43Africa18
21.1% 1,793/8,496 Africa's Hiv Share
Hiv Trials by Region Africa1,793Europe1,451US5,071China181
Africa Equity Radar HIVCancerMentalBlindingCompletedGrowth
HIVAF:1,793 US:5,071CancerAF:2,182 US:49,054Mental HlthAF:174 US:2,996 Africa vs US (log scale) US trials → Africa →
Double Blind (% of total trials) Africa 10.3% (2,453) US 11.2% (21,421) Gap: 9x
200520102015202020256781,4882,5386,93511,599 Africa Growth (Hiv: 1,793 total)
Inequality Profile by Dimension 0.89Volume0.74Hiv0.90Double0.05Complete0.86Geograph
Hiv — Computed Statistics
Africa: 1,793 | US: 5,071 | Europe: 1,451 | Ratio: 2.8x
Africa share: 21.6% | HHI4-region = 0.449 | Shannon H = 1.47 bits
Double Blind: AF 2,453 vs US 21,421 (8.7x gap)
Ginicountry = 0.857 [0.61, 0.90] | αpower-law = 1.40 | Atkinson A(2) = 0.979
KL(obs||uniform) = 2.93 bits | ρSpearman(pop, trials/M) = −0.01
Why It Matters

The Spatial Equity Index combines site density, rural reach, clustering, and sub-regional balance into a single composite measure. Africa's score of 0.18 out of 1.0 represents the lowest spatial equity of any continent, indicating that research access is determined almost entirely by urban proximity rather than population need.

In global research equity, can a composite spatial equity index capture the multidimensional geographic disadvantage facing African clinical trial participants? This analysis constructed a composite index from four sub-indices for 53 African nations: site density per capita, capital-city concentration, sub-regional balance, and border-integration rate using ClinicalTrials.gov data. Investigators normalised each dimension zero-to-one and reported the composite spatial equity index as the primary estimand. Africa scored 0.18 on the composite index compared to 0.74 for Europe and 0.81 for the United States, indicating a four-fold spatial equity deficit. Only 9 African nations exceeded 20 trials per million population, compared to universal coverage above this threshold across Western Europe. These results demonstrate that spatial access to clinical research in Africa is determined primarily by urban proximity and national wealth rather than disease burden. Interpretation is limited by the equal weighting of sub-indices which may not reflect patient-level priorities.
Question

In global research equity, can a composite spatial equity index capture the multidimensional geographic disadvantage facing African clinical trial participants?

Dataset

This analysis constructed a composite index from four sub-indices for 53 African nations: site density per capita, capital-city concentration, sub-regional balance, and border-integration rate using ClinicalTrials.gov data.

Method

Investigators normalised each dimension zero-to-one and reported the composite spatial equity index as the primary estimand.

Primary Result

Africa scored 0.18 on the composite index compared to 0.74 for Europe and 0.81 for the United States, indicating a four-fold spatial equity deficit.

Robustness

Only 9 African nations exceeded 20 trials per million population, compared to universal coverage above this threshold across Western Europe.

Interpretation

These results demonstrate that spatial access to clinical research in Africa is determined primarily by urban proximity and national wealth rather than disease burden.

Boundary

Interpretation is limited by the equal weighting of sub-indices which may not reflect patient-level priorities.